Immatics N.V. focuses on developing immunotherapies targeting the intracellular cancer antigen PRAME, employing cutting-edge T-cell receptor technology to circumvent limitations of conventional therapies. The company's recent years have been marked by substantial growth in clinical-stage programs and strategic collaborations, supported by significant equity capital raises and a robust cash position as of year-end 2025. Despite posting a sizeable net loss in 2025, largely due to escalating R&D expenditures amid ongoing clinical activities, Immatics is preparing for potential commercial launches, backed by state-of-the-art manufacturing facilities and alliances with partners such as Moderna and Bristol Myers Squibb. The biopharma faces key risks from competitive advances, regulatory complexities, financing variability from collaboration revenues, and manufacturing dependencies; monitoring milestone achievements and regulatory progress will be critical indicators of future performance.